In vivo inhibition of proteasome activity and tumour growth by Murraya koenigii leaf extract in breast cancer xenografts and by its active flavonoids in breast cancer cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 12, 2016, Pages 1605-1614

  Noolu, Bindu ^a   Gogulothu, Ramesh ^a   Bhat, Mehrajuddin ^a   Qadri, Syed S Y H ^a   Sudhakar Reddy, V ^a   Bhanuprakash Reddy, G ^a   Ismail, Ayesha ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

Author keywords

Apoptosis; Breast cancer; Flavonoid; Murraya koenigii; Proteasome; Xenografts

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APIGENIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPASE 3; CHOLESTEROL; CHYMOTRYPSIN; CREATININE; KAEMPFEROL; MURRAYA KOENIGII EXTRACT; MYRICETIN; PROTEASOME; PROTEIN BAX; QUERCETIN; RUTOSIDE; SYNAPTOPHYSIN; TRIACYLGLYCEROL; TRYPTASE; ANTINEOPLASTIC AGENT; FLAVONOID; PLANT EXTRACT; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG OVERDOSE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; MURRAYA KOENIGII; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; ISOLATION AND PURIFICATION; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MURRAYA; NUDE MOUSE; PATHOLOGY; PLANT LEAF; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLAVONOIDS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MURRAYA; PLANT EXTRACTS; PLANT LEAVES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84995961310     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520616666160520112210     Document Type: Article

References (50)

1. 1] Hortobagyi, G.N.; De la Garza Salazar, J.; Pritchard, K.; Amadori, D.; Haidinger, R.; Hudis, C.A.; Khaled, H.; Liu M.C.; Martin, M.; Namer, M.; O'Shaughnessy, J.A.; Shen Z.Z.; Albain, K.S. ABREAST Investigators. The global breast can cer burden: Variations in epidemiology and survival. Clin. Breast Cancer, 2005, 6(5), 391-401.
2. 2] Coughlin, S.S.; Ekwueme, D.U. Breast cancer as a global health concern: Cancer Epidemiol., 2009, 33(5), 315-318.
3. 3] Youlden, D.R.; Cramb, S.M.; Dunn, N.A.; Muller, J.M.; Pyke, C.M.; Baade, P.D. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol., 2012, 36(3), 237-248.
4. 4] Green, M.; Raina, V. Epidemiology: Screening and diagnosis of breast cancer in the Asia-Pacific region: Current perspectives and important considerations. Asi. Pac. J. Clin. Oncol., 2008, 4, 5-13.
5. 5] Agarwal, G.; Pradeep, P.V.; Aggarwal, V.; Yip, C.H.; Cheung, P.S. Spectrum of breast cancer in Asian women. World J Surg., 2007, 31(5), 1031-1040.
6. 6] Khokhar, A. Breast cancer in India: Where do we stand and where do we go? Asi. Pac. J. Cancer Prev., 2012, 13(10), 4861-4866.
7. 7] Nayak, A.; Banerji, J.; Banerji, A.; Mandal, S. Review on chemistry and pharmacology of murraya koenigii spreng (Rutaceae). J. Chem. Pharm. Res., 2010, 2, 286-299.
8. 8] Pruthi, J.S. Spices and condiments. New Delhi: National Book Trust India, 1976.
9. 9] Arulselvan, P.; Senthilkumar, G.P.; Sathish Kumar, D.; Subramanian, S. Anti-diabetic effect of Murraya koenigii leaves on streptozotocin induced diabetic rats. Pharmazie, 2006, 61(10), 874-877.
10. 10] Kesari, A.N.; Kesari, S.; Singh, S.K.; Gupta, R.K.; Watal, G. Studies on the glycemic and lipidemic effect of Murraya koenigii in experimental animals. J. Ethnopharmacol., 2007, 112(2), 305-311.
11. 11] Gupta, S.; George, M.; Singhal, M.; Sharma, G.N.; Garg, V. Leaves extract of murraya koenigii linn for anti-inflammatory and analgesic activity in animal models. J. Adv. Pharm. Technol. Res., 2010, 1(1), 68-77.
12. 12] Shah, A.S.; Wakade, A.S.; Juvekar, A.R. Immunomodulatory activity of methanolic extract of Murraya koenigii (L) Spreng. Leaves. Ind. J. Exp. Biol., 2008, 46(7), 505-509.
13. 13] Amin, K.S.; Jagadeesh, S.; Baishya, G.; Rao, P.G.; Barua, N.C.; Bhattacharya, S.; Banerjee, P.P. A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signalling in human prostate cancer cells. Mol. Cancer Ther., 2014, 13(2), 341-352.
14. 14] Ito, C.; Itoigawa, M.; Nakao, K.; Murata, T.; Tsuboi, M.; Kaneda, N.; Furukawa, H. Induction of apoptosis by carbazole alkaloids isolated from Murraya koenigii. Phytomedicine, 2006, 13(5), 359-365.
15. 15] Bhattacharya, K.; Samanta, S.K.; Tripathi, R.; Mallick, A.; Chandra, S.; Pal, B.C.; Shaha, C.; Mandal, C. Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signalling and the Bid protein and via mitochondrial pathways. Biochem. Pharmacol., 2010, 79(3), 361-372.
16. 16] Ayesha, I.; Bindu, N.; Shulagna, S.; Chandana, M.; Mehrajuddin, B.; Manchala, R. Proteasome inhibitory potential of commonly consumed dietary ingredients. Int. J. Food Nutr. Sci., 2012, 1(4), 27-31.
17. 17] Chen, D.; Daniel, K.G.; Chen, M.S.; Kuhn, D.J.; Landis-Piwowar, K.R.; Dou, Q.P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol., 2005, 69(10), 1421-1432.
18. 18] Pettinari, A.; Amici, M.; Cuccioloni, M.; Angeletti, M.; Fioretti, E.; Eleuteri, A.M. Effect of polyphenolic compounds on the proteolytic activities of constitutive and immuno-proteasomes. Antioxid. Redox. Signal., 2006, 8(1-2), 121-129.
19. 19] Goldberg, A.L. Functions of the proteasome: The lysis at the end of the tunnel. Science, 1995, 268(5210), 522-523.
20. 20] Hochstrasser, M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol., 1995, 7(2), 215-223.
21. 21] Dou, Q.P.; Li, B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist.Update, 1999, 2(4), 215-223.
22. 22] An, B.; Goldfarb, R.H.; Siman, R.; Dou, Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ., 1998, 5(12), 1062-1075.
23. 23] Kazi, A.; Urbizu, D.A.; Kuhn, D.J.; Acebo, A.L.; Jackson, E.R.; Greenfelder, G.P.; Kumar N.B.; Dou, Q.P. A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int. J. Mol. Med., 2003, 12(6), 879-887.
24. 24] Noolu, B.; Ajumeera, R.; Chauhan, A.; Nagalla, B.; Manchala, R.; Ismail, A. Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells. BMC Complement. Altern. Med., 2013, 13, 7.
25. 25] Noolu, B.; Ismail, A. Anti-proliferative and proteasome inhibitory activity of Murraya koenigii leaf extract in Human Cancer Cell Lines. Discov. Phytomedicine, 2015, 2, 1-9.
26. 26] Crozier, A.; Jensen, E.; Lean, M.E.J.; Mcdonald, M.S. Quantitative analysis of flavonoids by reversed-phase high-performance liquid chromatography. J. Chromatrog. A, 1997, 761, 315-321.
27. 27] Reddy, V.S.; Kumar, C.H.U.; Raghu, G.; Reddy, G.B. Expression and induction of small heat shock proteins in rat heart under chronic hyperglycemic conditions. Arch. Biochem. Biophys., 2014, 558, 1-9.
28. 28] Bhat, M.; Noolu, B.; Qadri, S.S.; Ismail, A. Vitamin D deficiency decreases adiposity in rats and causes altered expression of uncoupling proteins and steroid receptor coactivator3. J. Ster. Biochem. Mol. Biol., 2014, 144(B), 304-312.
29. 29] Metri, K.; Bhargav, H.; Chowdhury, P.; Koka, P.S. Ayurveda for chemo-radiotherapy induced side effects in cancer patients. J. Stem Cells, 2013, 8(2), 115-129.
30. 30] Adams, M.; Jewell, A.P. The use of complementary and alternative medicine by cancer patients. Int. Semin. Surg Oncol., 2007, 4, 10.
31. 31] Chevallier, A. The encyclopedia of medicinal plants. London: Dorlon Kindersley Publisher., 1996.
32. 32] Sivarajan, V.V.; Balachandran, I. Ayurvedic drugs and their plant sources. New Delhi: Oxford & IBH Publishing, 1994.
33. 33] Wada, M.; Kosaka, M.; Saito, S.; Sano, T.; Tanaka, K.; Ichihara, A. Serum concentrations and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J. Lab Clin. Med., 1993, 121, 215-223.
34. 34] Delic, J.; Masdehors, P.; Omura, S.; Cosset, J.M.; Dumont, J.; Binet, J.L.; Magdelenat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radio resistant human chronic lymphocytic leukemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Cancer, 1998, 77(7), 1103-1107.
35. 35] Ghasemzadeh, A.; Jaafar, H.Z.; Rahmat, A.; Devarajan, T. Evaluation of bioactive compounds, pharmaceutical quality, and anticancer activity of curry leaf (Murraya koenigii L.). Evid. Based Complement. Alternat. Med., 2014.
36. 36] Singh, P.A.; Wilson, T.; Luthria, D.; Freeman, R.M.; Scott, M.R.; Bilenker, D.; Shah, S.; Somasundaram, S.; Vorsa, N. LC-MS-MS characterisation of curry leaf flavonols and antioxidant activity. Food Chem., 2011, 127, 80-85.
37. 37] Vijayababu, M.R.; Kanagaraj, P.; Arunkumar, A.; Ilangovan, R.; Aruldhas, M.M.; Arunakaran, J. Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells (PC-3) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. J. Cancer Res. Clin. Oncol., 2005, 131(11), 765-771.
38. 38] Chen, D.; Landis-Piwowar, K.R.; Chen, M.S.; Dou, Q.P. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res., 2007, 9(6), R80.
39. 39] Li, F.; Ambrosini, G.; Chu, E.Y.; Plescia, J.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998, 396, 580-584.
40. 40] Salvesen, G.S.; Duckett, C.Z. IAP proteins: Blocking the road to death’s door. Nat. Rev. Mol. Cell Biol., 2002, 3, 401-410.
41. 41] LaCasse, E.C.; Mahoney, D.J.; Cheung, H.H.; Plenchette, S.; Baird, S.; Korneluk, R.G. IAP-targeted therapies for cancer. Oncogene., 2008, 27, 6252-6275.
42. 42] Yamamoto, H.; Ngan, C.Y.; Monden, M. Cancer cells survive with survivin. Cancer Sci., 2008, 99, 1709-1714.
43. 43] Jha, K.; Shukla, M.; Pandey, M. Survivin expression and targeting in breast cancer. Surg. Oncol., 2012, 21(2), 125-131.
44. 44] Orlowski, R.Z.; Kuhn, D.J. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin. Cancer Res., 2008, 14(6), 1649-1657.
45. 45] Gourley, M.; Williamson, J.S. Angiogenesis: New targets for the development of anticancer chemotherapies. Curr. Pharm. Des., 2000, 6(4), 417-439.
46. 46] Ryan, C.J.; Wilding, G. Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging., 2000, 17(4), 249-255.
47. 47] Gartel, A.L. A new target for proteasome inhibitors: FoxM1. Exp. Opin. Invest. Drugs, 2010, 19(2), 235-242.
48. 48] Bartlett, J.M. Biomarkers and patient selection for PI3K/Akt/ mTOR targeted therapies: Current status and future directions. Clin Breast Cancer Suppl., 2010, 3, S86-S95.
49. 49] Wagner, E.F; Nebreda, A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer, 2009, 9, 537-549.
50. 50] Yu, C.; Rahmani, M.; Dent, P.; Grant, S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp. Cell Res., 2004, 295, 555-566.